Merck Agrees to Return Kuvan Rights to BioMarin Pharmaceutical

02-Oct-2015 - Merck announced that it has reached an agreement with BioMarin Pharmaceutical, Inc., San Rafael, California, U.S., to return the rights to Kuvan, used to treat phenylketonuria (PKU), a rare metabolism disorder, as the company focuses its healthcare business on core areas. In addition to Kuvan®, ...

Merck Serono's Kuvan Recommended for European Approval

CHMP Issued Positive Opinion Recommending Marketing Authorization of Kuvan(R) for the Treatment of hyperphenylalaninemia in Patients With phenylketonuria or BH4 Deficiency

30-Sep-2008 - Merck Serono, a division of Merck KGaA announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), issued a positive opinion for Kuvan(R) (sapropterin dihydrochloride) as an oral treatment for hyperphenylalaninemia ...

BioMarin Forms Strategic Partnership With Daiichi Suntory Pharma to Develop New Drug

24-Nov-2004 - BioMarin Pharmaceutical Inc. has entered into a strategic business partnership with Daiichi Suntory Pharma Co., Ltd., for Phenoptin(TM) (sapropterin hydrochloride), an investigational oral enzyme cofactor for the treatment of the genetic disease phenylketonuria (PKU). This partnership provides ...